Literature DB >> 29337277

Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease.

Kamin Kim1, Nicolaas I Bohnen2, Martijn L T M Müller3, Cindy Lustig4.   

Abstract

Executive functions are complex both in the cognitive operations involved and in the neural structures and functions that support those operations. This complexity makes executive function highly vulnerable to the detrimental effects of aging, brain injury, and disease, but may also open paths to compensation. Neural compensation is often used to explain findings of additional or altered patterns of brain activations by older adults or patient populations compared to young adults or healthy controls, especially when associated with relatively preserved performance. Here we test the hypothesis of an alternative form of compensation, between different neuromodulator systems. 135 patients with Parkinson's Disease (PD) completed vesicular monoamine transporter type2 (VMAT2) and acetylcholinesterase PET scanning to assess the integrity of nigrostriatal dopaminergic, thalamic cholinergic, and cortical cholinergic pathways, and a behavioral test (Stroop + task-switching) that puts high demands on conflict processing, an important aspect of executive control. Supporting the compensatory hypothesis, regression models controlling for age and other covariates revealed an interaction between caudate dopamine and cortical cholinergic integrity: Cortical cholinergic integrity was a stronger predictor of conflict processing in patients with relatively low caudate dopaminergic function. These results suggest that although frontostriatal dopaminergic function plays a central role in executive control, cholinergic systems may also make an important contribution. The present results suggest potential pathways for remediation, and that the appropriate interventions for each patient may depend on their particular profile of decline. Furthermore, they help to elucidate the brain systems that underlie executive control, which may be important for understanding other disorders as well as executive function in healthy adults.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29337277      PMCID: PMC6041186          DOI: 10.1016/j.neuroimage.2018.01.021

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  93 in total

Review 1.  Cognition through the lifespan: mechanisms of change.

Authors:  Fergus I M Craik; Ellen Bialystok
Journal:  Trends Cogn Sci       Date:  2006-02-07       Impact factor: 20.229

2.  G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.

Authors:  Franz Faul; Edgar Erdfelder; Albert-Georg Lang; Axel Buchner
Journal:  Behav Res Methods       Date:  2007-05

Review 3.  Direct and indirect pathways of basal ganglia: a critical reappraisal.

Authors:  Paolo Calabresi; Barbara Picconi; Alessandro Tozzi; Veronica Ghiglieri; Massimiliano Di Filippo
Journal:  Nat Neurosci       Date:  2014-07-28       Impact factor: 24.884

Review 4.  Region-specific changes in prefrontal function with age: a review of PET and fMRI studies on working and episodic memory.

Authors:  M Natasha Rajah; Mark D'Esposito
Journal:  Brain       Date:  2005-07-27       Impact factor: 13.501

5.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

6.  Cognitive deficits in the early stages of Parkinson's disease.

Authors:  A J Lees; E Smith
Journal:  Brain       Date:  1983-06       Impact factor: 13.501

7.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

Authors:  B Scatton; F Javoy-Agid; L Rouquier; B Dubois; Y Agid
Journal:  Brain Res       Date:  1983-09-26       Impact factor: 3.252

8.  Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.

Authors:  H Shimada; S Hirano; H Shinotoh; A Aotsuka; K Sato; N Tanaka; T Ota; M Asahina; K Fukushi; S Kuwabara; T Hattori; T Suhara; T Irie
Journal:  Neurology       Date:  2009-05-27       Impact factor: 9.910

Review 9.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

10.  Dissociating proactive and reactive control in the Stroop task.

Authors:  Corentin Gonthier; Todd S Braver; Julie M Bugg
Journal:  Mem Cognit       Date:  2016-07
View more
  5 in total

Review 1.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

Review 2.  Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson's disease.

Authors:  Roger L Albin; Sygrid van der Zee; Teus van Laar; Martin Sarter; Cindy Lustig; Martijn L T M Muller; Nicolaas I Bohnen
Journal:  Prog Brain Res       Date:  2022-02-04       Impact factor: 2.453

Review 3.  Imaging Markers of Progression in Parkinson's Disease.

Authors:  Antonio P Strafella; Nico I Bohnen; Nicola Pavese; David E Vaillancourt; Thilo van Eimeren; Marios Politis; Alessandro Tessitore; Christine Ghadery; Simon Lewis
Journal:  Mov Disord Clin Pract       Date:  2018-10-09

4.  Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment.

Authors:  Sygrid van der Zee; Prabesh Kanel; Marleen J J Gerritsen; Jeffrey M Boertien; Anne C Slomp; Martijn L T M Müller; Nicolaas I Bohnen; Jacoba M Spikman; Teus van Laar
Journal:  Mov Disord       Date:  2022-01-17       Impact factor: 9.698

5.  Graphene-Based Nanoparticles as Potential Treatment Options for Parkinson's Disease: A Molecular Dynamics Study.

Authors:  Ehsan Alimohammadi; Mohammad Khedri; Ahmad Miri Jahromi; Reza Maleki; Milad Rezaian
Journal:  Int J Nanomedicine       Date:  2020-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.